JP2009538896A5 - - Google Patents

Download PDF

Info

Publication number
JP2009538896A5
JP2009538896A5 JP2009512681A JP2009512681A JP2009538896A5 JP 2009538896 A5 JP2009538896 A5 JP 2009538896A5 JP 2009512681 A JP2009512681 A JP 2009512681A JP 2009512681 A JP2009512681 A JP 2009512681A JP 2009538896 A5 JP2009538896 A5 JP 2009538896A5
Authority
JP
Japan
Prior art keywords
oxo
methyl
dihydropyridazin
fluorobenzoyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009512681A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009538896A (ja
JP5351755B2 (ja
Filing date
Publication date
Priority claimed from GBGB0610680.1A external-priority patent/GB0610680D0/en
Application filed filed Critical
Publication of JP2009538896A publication Critical patent/JP2009538896A/ja
Publication of JP2009538896A5 publication Critical patent/JP2009538896A5/ja
Application granted granted Critical
Publication of JP5351755B2 publication Critical patent/JP5351755B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009512681A 2006-05-31 2007-05-25 ポリ(adp−リボース)ポリメラーゼ(parp)インヒビターとしてのピリジノン及びピリダジノン誘導体 Active JP5351755B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0610680.1A GB0610680D0 (en) 2006-05-31 2006-05-31 Therapeutic compounds
GB0610680.1 2006-05-31
PCT/GB2007/050295 WO2007138351A2 (en) 2006-05-31 2007-05-25 Pyridinone and pyridazinone derivatives as inhibitors of poly(adp-ribose)polymerase (parp)

Publications (3)

Publication Number Publication Date
JP2009538896A JP2009538896A (ja) 2009-11-12
JP2009538896A5 true JP2009538896A5 (OSRAM) 2013-08-22
JP5351755B2 JP5351755B2 (ja) 2013-11-27

Family

ID=36694627

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009512681A Active JP5351755B2 (ja) 2006-05-31 2007-05-25 ポリ(adp−リボース)ポリメラーゼ(parp)インヒビターとしてのピリジノン及びピリダジノン誘導体

Country Status (16)

Country Link
US (1) US8188084B2 (OSRAM)
EP (1) EP2029551B1 (OSRAM)
JP (1) JP5351755B2 (OSRAM)
KR (1) KR101529891B1 (OSRAM)
CN (2) CN103420988A (OSRAM)
AU (1) AU2007266836B2 (OSRAM)
BR (1) BRPI0711741B8 (OSRAM)
CA (1) CA2653529C (OSRAM)
ES (1) ES2702781T3 (OSRAM)
GB (1) GB0610680D0 (OSRAM)
IL (1) IL195113A (OSRAM)
MX (1) MX2008015014A (OSRAM)
NO (1) NO343950B1 (OSRAM)
NZ (1) NZ572815A (OSRAM)
WO (1) WO2007138351A2 (OSRAM)
ZA (1) ZA200809238B (OSRAM)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0622195D0 (en) * 2006-11-08 2006-12-20 Angeletti P Ist Richerche Bio Therapeutic agents
ES2524787T3 (es) 2007-11-15 2014-12-12 Msd Italia S.R.L. Derivados de piridazinona como inhibidores de PARP
DE102008019907A1 (de) * 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
JP5654001B2 (ja) * 2009-04-29 2015-01-14 グラクソ グループ リミテッドGlaxo Group Limited P2X7調節因子としての5,6,7,8−テトラヒドロ[1,2,4]トリアゾロ[4,3−a]ピラジン誘導体
GB0907515D0 (en) * 2009-04-30 2009-06-10 Glaxo Group Ltd Compounds
US10065960B2 (en) 2010-04-02 2018-09-04 Ogeda Sa NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
JP5822911B2 (ja) * 2010-04-02 2015-11-25 ユーロスクリーン エス.エー. 新規のnk−3受容体選択的アンタゴニスト化合物、医薬組成物、及びnk−3受容体媒介疾患における使用方法
AU2011251622A1 (en) 2010-05-10 2012-12-20 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
CN102372716A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
TWI577693B (zh) 2011-05-31 2017-04-11 江蘇康緣藥業股份有限公司 聚(adp-核糖)聚合酶之三環抑制劑
KR102049534B1 (ko) 2011-10-03 2019-11-27 오게다 에스.에이. 선택적 NK-3 수용체 길항제로서의 신규한 키랄 N-아실-5,6,7,(8-치환된)-테트라히드로-[1,2,4]트리아졸로[4,3-a]피라진, 의약 조성물, NK-3 수용체 매개 질환에 사용하는 방법 및 그의 키랄 합성법
CN103570725B (zh) 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
CN103833756B (zh) * 2012-11-26 2016-12-21 中国科学院上海药物研究所 一类哒嗪酮类化合物及其制备方法和用途
ES2469990B1 (es) * 2012-12-19 2015-01-26 Universidade De Vigo Compuestos de estructura híbrida piridazinona ditiocarbamato con actividad antineoplásica
CA2890309A1 (en) * 2012-12-31 2014-07-03 Cadila Healthcare Limited Substituted phthalazin-1 (2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1
HRP20201211T1 (hr) * 2013-03-13 2020-11-13 Chugai Seiyaku Kabushiki Kaisha Derivat dihidropiridazin-3,5-diona
MY191366A (en) 2013-03-13 2022-06-20 Forma Therapeutics Inc Novel compounds and compositions for inhibition of fasn
JP6275242B2 (ja) 2013-03-29 2018-02-07 オゲダ エス.エー. 選択的NK−3受容体拮抗薬としての新規なN−アシル−(3位置換)−(8−メチル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン、その医薬組成物、NK−3受容体媒介性障害で使用する方法
KR102364835B1 (ko) 2013-03-29 2022-02-17 오게다 에스.에이. 선택적 NK-3 수용체 길항제로서의 신규한 N-아실-(3-치환)-(8-치환)-5,6-디히드로-[1,2,4]트리아졸로[4,3-a]피라진, 약학적 조성물, NK-3 수용체-매개 질환에 사용하기 위한 방법
WO2014154896A1 (en) 2013-03-29 2014-10-02 Euroscreen Sa NOVEL N-ACYL-(3-SUBSTITUTED)-5,6,7,8-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS
US10183948B2 (en) 2013-03-29 2019-01-22 Ogeda Sa N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
KR101670126B1 (ko) 2013-09-13 2016-10-27 일동제약(주) 신규 프탈라지논 유도체 및 그 제조방법
ES2544869B2 (es) * 2014-03-04 2016-01-18 Universidade De Vigo Derivados de piridazin-3(2H)-ona inhibidores selectivos de la isoforma B de la monoaminooxidasa
WO2016054237A2 (en) * 2014-10-03 2016-04-07 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Poly (adp-ribose) polymerase 1 inhibitors structurally unrelated to nad
US10472664B2 (en) 2014-10-03 2019-11-12 Institute For Cancer Research Screening assay for identification of poly(ADP-ribose) polymerase 1 inhibitors
EP3265560B1 (en) 2015-03-02 2021-12-08 Sinai Health System Homologous recombination factors
EP3325623B3 (en) 2015-07-23 2021-01-20 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
CN106749261A (zh) * 2015-11-23 2017-05-31 中国科学院上海药物研究所 一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
JP6594570B2 (ja) 2017-03-20 2019-10-23 フォーマ セラピューティクス,インコーポレイテッド ピルビン酸キナーゼ(pkr)活性化剤としてのピロロピロール組成物
CN109232575B (zh) * 2017-07-10 2022-01-25 中国科学院上海药物研究所 吡咯[1,2-b]哒嗪类化合物或其可药用盐及它们的用途
WO2019175132A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
MA52486B1 (fr) * 2018-04-30 2023-04-28 Ribon Therapeutics Inc Pyridazinones utilisés en tant qu'inhibiteurs de parp7
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
WO2020061378A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
WO2020223229A1 (en) 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
AU2020350763A1 (en) 2019-09-19 2022-04-07 Novo Nordisk Health Care Ag Pyruvate kinase R (PKR) activating compositions
US11691969B2 (en) 2019-10-30 2023-07-04 Ribon Therapeutics, Inc. Pyridazinones as PARP7 inhibtors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
BR112022021321A2 (pt) 2020-04-21 2022-12-20 Idience Co Ltd Formas cristalinas do composto de ftalazinona.
US12060345B2 (en) 2020-04-21 2024-08-13 Idience Co., Ltd. Process for preparing a phthalazinone derivative and intermediates thereof
US12059419B2 (en) 2020-10-16 2024-08-13 Idience Co., Ltd. Pharmaceutical composition comprising phthalazinone derivatives
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
CN117083274A (zh) * 2021-04-23 2023-11-17 四川海思科制药有限公司 一种并环杂环衍生物及其在医药上的应用
CN115477640A (zh) * 2021-05-31 2022-12-16 由理生物医药(上海)有限公司 作为parp7抑制剂的哒嗪酮类化合物
JP2024539252A (ja) * 2021-10-28 2024-10-28 ギリアード サイエンシーズ, インコーポレイテッド ピリジジン-3(2h)-オン誘導体
CN115745971B (zh) * 2021-12-20 2024-07-30 北京华森英诺生物科技有限公司 Parp7抑制剂及其应用
WO2023185073A1 (zh) * 2022-04-01 2023-10-05 诺沃斯达药业(上海)有限公司 Parp7抑制剂及其用途
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2024261243A1 (en) 2023-06-21 2024-12-26 Hemispherian As Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622948A (en) 1994-12-01 1997-04-22 Syntex (U.S.A.) Inc. Pyrrole pyridazine and pyridazinone anti-inflammatory agents
CN1136197C (zh) * 1996-05-30 2004-01-28 霍夫曼-拉罗奇有限公司 新的哒嗪酮衍生物
GB2384776C (en) 2000-10-30 2006-02-03 Kudos Pharm Ltd Phthalazinone derivatives
DE60218458T2 (de) 2001-05-08 2007-11-15 Kudos Pharmaceuticals Ltd. Isochinolinon derivate als parp inhibitoren
WO2003011293A2 (en) * 2001-08-02 2003-02-13 Neurocrine Biosciences, Inc. Pyridinone and pyridazinone derivatives as gonadotropin-releasing hormone receptor antagonists
WO2003017369A1 (en) 2001-08-14 2003-02-27 Transchip, Inc. A pixel sensor with charge evacuation element and systems and methods for using such
ES2357057T3 (es) 2002-04-30 2011-04-15 Kudos Pharmaceuticals Limited Derivados de ftalazinona.
KR101146806B1 (ko) 2003-03-12 2012-05-22 메이브릿지 리미티드 프탈라지논 유도체
MXPA05010081A (es) * 2003-03-24 2005-11-23 Hoffmann La Roche Bencil-piridazinonas como inhibidores de transcriptasa inversa.
JP4627315B2 (ja) * 2004-03-23 2011-02-09 エフ.ホフマン−ラ ロシュ アーゲー 非ヌクレオシド逆転写酵素阻害剤としてのベンジルピリダジノン誘導体
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
CA2563225A1 (en) * 2004-04-15 2005-10-27 F. Hoffmann-La Roche Ag Process for preparing pyridazinone compounds
NZ553979A (en) 2004-08-26 2009-05-31 Kudos Pharm Ltd 4-heteroarylmethyl substituted phthalazinone derivatives
CA2614529C (en) * 2005-07-21 2011-06-28 F. Hoffmann-La Roche Ag Pyridazinone derivatives as thyroid hormone receptor agonists
CA2623728A1 (en) * 2005-09-30 2007-04-12 F. Hoffmann-La Roche Ag Nnrt inhibitors
WO2007113596A1 (en) * 2006-04-03 2007-10-11 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors
AU2007266840B2 (en) * 2006-05-31 2012-09-20 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Pyrrolo[1,2-A]pyrazin-1(2H)-one and pyrrolo[1,2-D][1,2,4]triazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose)polymerase(PARP)
US8466150B2 (en) * 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
SI2698062T1 (sl) * 2006-12-28 2015-12-31 Abbvie Inc. Inhibitorji poli (ADP-riboza) polimeraze
US20080280910A1 (en) 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
TW200900396A (en) 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
US20090023727A1 (en) 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
WO2011055270A1 (en) * 2009-11-04 2011-05-12 Wyeth Llc Indole based receptor crth2 antagonists

Similar Documents

Publication Publication Date Title
JP2009538896A5 (OSRAM)
RU2405771C2 (ru) Гетероциклические замещенные фенилметаноны в качестве ингибиторов переносчика глицина 1
RU2503676C2 (ru) Пирролопиразиновые ингибиторы киназы
AU2019240299B2 (en) SHP2 phosphatase inhibitors and methods of use thereof
JP2014506929A5 (OSRAM)
ES2778700T3 (es) Nuevos derivados de piperidinilo sustituidos con (hetero)arilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
RU2005117383A (ru) Производные фенилаланина в качестве ингибиторов дипептидилпептидазы для лечения или профилактики диабета
RU2443706C2 (ru) Фармацевтические соединения
AU2011253057B2 (en) Nitrogen heterocyclic compounds useful as PDE10 inhibitors
JP2011500774A5 (OSRAM)
JP2021503004A5 (OSRAM)
BR112021001292A2 (pt) compostos heterobicíclicos para inibir a atividade de shp2
JP2011516512A5 (ja) 新規な置換スピロ[シクロアルキル−1,3'−インドール]−2'(1'H)−オン誘導体およびp38マイトジェン活性化タンパク質キナーゼ阻害剤としてのそれらの使用
HRP20120105T1 (hr) Aminoheterociklički spojevi
WO2025049746A1 (en) Compositions comprising werner syndrome helicase inhibitors and methods of using the same
JP2018522046A5 (OSRAM)
JP2012510998A5 (OSRAM)
JP2010524984A5 (OSRAM)
RU2014123316A (ru) Ингибиторы фосфодиэстеразы типа 10а
AU2009218459A1 (en) Imidazo [1,2-B] pyridazine derivatives for the treatment of C-Met tyrosine kinase mediated disease
ME02330B (me) Derivati 2,3-dihidro-1h-inden-1-il-2,7-diazaspir0[3.6]nonana i njihova upotreba kao antagonista ili inverznih agonista grelinskog receptora
RU2015129538A (ru) Замещенные имидазопиридины в качестве ингибиторов hdm2
JP2013522238A5 (OSRAM)
RU2009125024A (ru) Соединения замещенных диазепанов в качестве антагонистов орексиновых рецепторов
JP2018529725A (ja) キナーゼ阻害剤としての縮合ピラゾール誘導体